Frederick National Lab: BRB Home Page

The NCI BRB Program Staff provide oversight of the Biopharmaceutical Development Program (BDP) at the National Cancer Institute Frederick campus (NCI-Frederick). The BDP produces a variety of biopharmaceuticals under current Good Manufacturing Practices (cGMP) for Phase I/II human clinical trials or advanced preclinical animal testing. The BDP is operated under contract by Scientific Applications International Corporation (SAIC) Frederick, which provides operations and technical support to the FCRDC.

Technical information about all materials provided by the Preclinical Repository are below:

Need to create a new MyNCIF Account?
Forgot your username or password?
Username:	*
Password:	*

The BRB Preclinical Repository is an NCI-sponsored facility containing bulk cytokines, monoclonal antibodies, reference standards, and other research reagents that are maintained under carefully controlled storage conditions. The purpose of this facility is to maintain and distribute a constant and uniform supply of high quality reagents for peer-reviewed scientists at non-profit institutions and specific materials to commercial establishments.

There is no charge for the reagents
Reagents can be ordered on the BRB Preclinical Repository ordering page

SHIPPING INFORMATION FOR BRB PRECLINICAL REPOSITORY

Shipping costs are the responsibility of the recipient. Investigators at not-for-profit institutions within the USA will not be charged a handling and packaging fee. Due to funding constraints, we must charge a HANDLING AND PACKAGING FEE for shipments outside the USA and to investigators at commercial establishments. Once you have placed your order, you will be contacted to arrange payment of the fee. Fed Ex, UPS or DHL account numbers or if required by recipient’s institution, a PDF of shipping label(s) are accepted.

NOTICE

The BRB is developing clinical and non-clinical supplies of some of the immunomodulating agents prioritized in the 2007 Immunotherapy Agent Workshop. Agents such as Ad-CCL21, IL-7, IL-12, IL-15 and MPL will be made available to the community, through a variety of standard mechanisms.

Limited amounts of the ch14.18 monoclonal antibody currently in Phase III clinical trials for neuroblastoma are available for investigators interested in identifying additional disease indications for this antibody. The antibody produced from SP2/0 hybridoma cells targets the disialoganglioside (GD2). Ch14.18 is suitable for use in ADCC or other assays requiring a humanized antibody. A murine version of the antibody (14.18G2a) is also available for immunohistochemistry studies. Hu 14.18-IL2 is available from the repository under the Other Reagents category. The 1A7 anti-idiotype antibody that recognizes GD2 antibodies will also be available from the repository after June 1, 2011.

For current development status and information on how to obtain one of these special agents, please contact Dr. Karen Muszynski.